Workplace Productivity Loss in Patients with Progressive Pulmonary Fibrosis: Data from the ILD-PRO Registry
Sharashchandra Shetty, Aparna C Swaminathan, Peide Li, Megan L Neely, Amy L Olson, Laurie D Snyder, the ILD-PRO Registry investigators · 2026
Read Workplace Productivity Loss in Patients with Progressive Pulmonary Fibrosis: Data from the ILD-PRO Registry by Sharashchandra Shetty, Aparna C Swaminathan, Peide Li, Megan L Neely, Amy L Olson, Laurie D Snyder, the ILD-PRO Registry investigators (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13319162.txt.
Introduction
Sharashchandra Shetty and co-authors measure, in 2026, lost work productivity among United States patients with progressive pulmonary fibrosis, a scarring lung disease. Breathlessness, cough and fatigue can all erode working life. Data came from a multicentre registry of patients with progressive scarring diseases other than the idiopathic form.
Among 597 patients who completed a work questionnaire, 175 were employed. In the previous week they worked about 33 hours on average and lost about 10 hours to their illness, split between absence and reduced performance while present. For those with any loss, the estimated yearly cost was substantial. Worse lung capacity and worse scores for breathlessness and cough impact raised the odds of productivity loss. The findings quantify a burden often hidden behind clinical measures.
Catalog record
| CREATOR | Sharashchandra Shetty, Aparna C Swaminathan, Peide Li, Megan L Neely, Amy L Olson, Laurie D Snyder, the ILD-PRO Registry investigators |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 30 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Workplace Productivity Loss in Patients with Progressive Pulmonary Fibrosis: Data from the ILD-PRO Registry Authors: Sharashchandra Shetty, Aparna C Swaminathan, Peide Li, Megan L Neely, Amy L Olson, Laurie D Snyder, the ILD-PRO Registry investigators Published: 2026 ABSTRACT AbstractPurposePulmonary fibrosis may impair an individual’s ability to work. We assessed the extent, cost and factors associated with workplace productivity loss among patients with progressive pulmonary fibrosis (PPF).MethodsThe multi-center ILD-PRO Registry enrolled US patients with progressive interstitial lung diseases (ILDs) other than idiopathic pulmonary fibrosis. Workplace productivity loss was assessed using the Work Productivity and Activity Impairment (WPAI) questionnaire. Associations between patient characteristics and workplace productivity loss among employed patients were analyzed using logistic regression.ResultsAmong 175 employed patients of 597 who completed the WPAI questionnaire, 58.3% were female, median age was 58 years, median forced vital capacity (FVC) was 58.7% predicted; 20.0% used oxygen with activity and at rest. In the past 7 days, mean (SD) hours worked was 32.9 (15.8) and mean (SD) working hours lost was 10 (12). Mean (SD) percentage of working hours lost was 24.4 (30.2). Mean (SD) working hours lost due to absenteeism and presenteeism were 4 (9) and 8 (11), respectively. Among patients with any productivity loss, the estimated mean (SD) annual cost of productivity loss was $24,815 ($17,917). Lower FVC % predicted, higher (worse) St. George’s Respiratory Questionnaire scores and lower (worse) Cough and Sputum Assessment Questionnaire cough impact and symptoms scores were associated with greater odds of productivity loss.ConclusionsPatients with PPF showed significant impairment in workplace productivity. Worse lung function and worse scores on patient-reported outcomes were associated with a greater likelihood of productivity loss.Trial Registration ClinicalTrials.gov; No: NCT01915511; registered August 5, 2013; URL: www.clinicaltrials.gov.Supplementary InformationThe online version contains supplementary material available at 10.1007/s00408-026-00895-x.Keywords: Absenteeism, Cost of illness, Interstitial lung diseases, Observational study, Presenteeism Introduction Worsening lung fibrosis associated with an interstitial lung disease (ILD) other than idiopathic pulmonary fibrosis (IPF) is referred to as progressive pulmonary fibrosis (PPF) [1]. Patients with fibrosing ILDs often experience symptoms such as dyspnea, cough and fatigue, which impair quality of life and worsen as the disease progresses [2–5]. Anxiety and depression are also common in patients with ILDs, particularly in those with more advanced disease [6, 7]. ILD and its associated symptoms have been shown to have a deleterious impact on a patient’s ability to engage in work [8–10], but the impact of PPF on work productivity is not well understood. We used data from the ILD-PRO Registry [11] to assess workplace productivity loss, its cost, and factors associated with workplace productivity loss, among patients with PPF. Methods The ILD-PRO Registry The ILD-PRO Registry enrolled patients aged ≥ 30 years with an ILD other than IPF that was diagnosed or confirmed at the enrolling center [11]. Eligible patients had reticular abnormality and traction bronchiectasis (with or without honeycombing) on a high-resolution computed tomography (HRCT) scan and/or lung biopsy and met at least one of the following criteria for ILD progression within the prior 24 months: relative decline in forced vital capacity (FVC) % predicted ≥ 10%; relative decline in diffusing capacity of the lungs for carbon monoxide (DLco) % predicted ≥ 10%; relative decline in FVC % predicted ≥ 5–<10% plus worsened respiratory symptoms and/or increased extent of fibrotic changes on HRCT; worsened respiratory symptoms plus increased extent of fibrotic changes on HRCT. At enrollment, retrospective data were collected from electronic medical records. Patients were then followed prospectively while receiving usual care. In addition, a call center contacted participants every 6 months to confirm vital status and interactions with healthcare systems. The study was approved by the Duke University Institutional Review Board (Pro00046131). The protocol was approved by the relevant Institutional Review Boards and/or local Independent Ethics Committees prior to patient enrolment. All patients provided written informed consent. Data for these analyses were extracted from the database in May 2025. Workplace Productivity Workplace productivity was assessed using the Work Productivity and Activity Impairment (WPAI) questionnaire (GH V2.0) [12, 13]. This questionnaire comprises six questions: one about whether the individual is employed and five about the effect of health problems on an individual’s ability to work and perform regular activities, with a recall period of 7 days (Table 1). The questionnaire was administered via the call center and was included in interviews from 16 August 2023 to 30 November 2024. Each participant only completed the questionnaire once. Table 1Responses to WPAI questionnaire among employed patients (n = 175)1Are you currently employed (working for pay)?175 (100)2How many hours did you miss from work because of your health problems?Include hours you missed on sick days, times you went in late, left early, etc., because of your health problems3.6 (9.5)3How many hours did you miss from work because of any other reason, such as vacation, holidays, time off to participate in this study?2.3 (6.5)4How many hours did you actually work?32.9 (15.8)5How much did your health problems affect your productivity while you were working? *2.4 (2.7)6How much did your health problems affect your ability to do your regular daily activities, other than work at a job?†3.3 (2.9)Data are n (%) or mean (SD). Questions two to six cover the previous 7 days*Scored from 0 to 10, where 0 indicates that “health problems had no effect on my work” and 10 indicates that “health problems completely prevented me from working”. Nine patients had missing data on this question†Scored from 0 to 10, where 0 indicates that “health problems had no effect on my daily activities” and 10 indicates that “health problems completely prevented me from doing my daily activities” Responses to WPAI questionnaire among employed patients (n = 175) How many hours did you miss from work because of your health problems? Include hours you missed on sick days, times you went in late, left early, etc., because of your health problems Data are n (%) or mean (SD). Questions two to six cover the previous 7 days *Scored from 0 to 10, where 0 indicates that “health problems had no effect on my work” and 10 indicates that “health problems completely prevented me from working”. Nine patients had missing data on this question †Scored from 0 to 10, where 0 indicates that “health problems had no effect on my daily activities” and 10 indicates that “health problems completely prevented me from doing my daily activities” Analyses The characteristics of patients who completed the WPAI questionnaire were analyzed descriptively. Age and payor information were based on data collected at enrollment. Other variables were based on values from the clinical encounter prior to administration of the WPAI questionnaire. Absenteeism was defined as the number of hours missed from work because of health problems (based on question two). Presenteeism was calculated as the number of hours worked (based on question four) multiplied by the impact of health problems on work productivity on a scale of 0 (score of 0 on question five, i.e. “health problems had no effect on my work”) to 0.1 (score of 10 on question five, i.e. health problems completely prevented me from working”). Total workplace productivity loss was the total of absenteeism and presenteeism. Among employed patients, the annual cost of workplace productivity loss was estimated based on the median usual